



Ref No: AWL/SECT/2021-22/03

February 15, 2022

**BSE Limited**  
Floor 25, P J Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code: 543458**

**National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip Code: AWL**

**Sub: Newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results of Adani Wilmar Limited ("the Company") for the Quarter and Nine months ended 31<sup>st</sup> December 2021.**

**Ref: SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**


Dear Sir / Madam,

Pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Unaudited Financial Results (Standalone & Consolidated) for the third quarter and nine months ended 31<sup>st</sup> December 2021 published in the following newspapers:

- i) Indian Express (English) dated February 14, 2022
- ii) Financial Express (Gujarati) dated February 14, 2022

You are requested to take the same on record.

Thanking you,  
Yours faithfully,  
**For Adani Wilmar Limited**



**Darshil Lakhia**  
**Company Secretary**  
**Memb. No: A20217**

Adani Wilmar Ltd.  
Fortune House  
Nr. Navrangpura Railway Crossing  
Ahmedabad – 380 009  
Gujarat, India  
CIN: U15146GJ1999PLC035320

Tel +91 79 2645 5650  
Fax +91 79 2645 5621  
info@adaniwilmar.in  
www.adaniwilmar.com

Registered Office: Fortune House, Nr. Navrangpura Railway Crossing, Ahmedabad 380 009, Gujarat, India

**SHREE BHAVYA FABRICS LIMITED**

CIN : L17119GJ1988PLC01120  
Regd. Off. : Survey No. 170, Pirana Road, Piplej, Ahmedabad, Gujarat, 382405  
Tel. : +91-79-22133383 • Email: csjd7bhavyafabrics@gmail.com

Extract of Unaudited Standalone Financial Results for the Quarter and Nine Months ended on 31st December, 2021

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		
		December 31, 2021	September 30, 2021	December 31, 2020	December 31, 2021	December 31, 2020	March 31, 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total income from Operations	4,289.20	4,455.37	5,236.61	11,375.72	9,493.19	14,534.54
2	Net Profit/(Loss) for the period (before Tax and Exceptional items)	(9.98)	16.34	159.83	21.19	(181.19)	17.96
3	Net Profit/(Loss) for the period (Before Tax and after Exceptional items)	(9.98)	16.34	159.83	21.19	(181.19)	17.96
4	Net Profit/(Loss) for the period (after Tax and Exceptional items)	(5.12)	7.21	155.36	17.11	(187.01)	3.37
5	Total Comprehensive Income for the period Profit/(Loss) for the period (After Tax) and other comprehensive income (after Tax)	(5.12)	7.21	155.36	17.11	(187.01)	3.37
6	Paid-up Equity share capital (face value of Rs. 10/-each share)	950.00	950.00	950.00	950.00	950.00	950.00
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)	-	-	-	-	-	1,953.38
8	Earnings Per Share (before and after extraordinary items) (of Rs. 10/- each) Basic and Diluted	(0.05)	0.08	1.64	0.18	(1.97)	0.04

**Notes:**  
1. The above result is an extracts of the details unaudited Financial Result for the Quarter and Nine Months ended 31st December, 2021 filed with the stock exchange under regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015. The full financial result for the Quarter and Nine Months ended on 31st December, 2021 are available on the website of the stock exchange i.e www.bseindia.com and website of the company i.e www.shreebhavyafabrics.com

For, **SHREE BHAVYA FABRICS LIMITED**  
**Purushottam R. AGARWAL**  
Managing Director  
(DIN: 00396869)

Place : Ahmedabad  
Date : 14.02.2022

**GUJARAT WATER SUPPLY & SEWERAGE BOARD, GANDHINAGAR**

Executive Engineer, P.H.W. Dn., Nakhtrana  
Tender Notice No. 14 & 6 (3<sup>rd</sup> Attempt) Year 2021-22

Executive Engineer, Public Health Works Division, Nakhtrana Kutch through e-tendering system in Work  
Providing, Supplying, Lowering, laying And Jointing Various Dia DI & PVC Pipeline, Construction and Designing of WTP and Storage at various Varnseda Complex villages, Pump house and compound wall at various headworks, Pumping Machinery For Varnseda Complex RWSS Augmentation Scheme (Under Nal Se Jal Programme 2020-21 Varnseda Complex) Ta: Nakhtrana & Bhuj (31<sup>st</sup> Attempt)  
Estimated Cost Rs.7,14,58,750.60 (Tender ID No. 506052)  
Providing, Supplying, Lowering, laying And Jointing Various Dia DI & PVC Pipeline, Construction Storage at various villages, Pump house and compound wall at various Head works, Pumping Machinery and 5 year O&M Work For Sutbari RWSS Augmentation Scheme (Under Nal Se Jal Programme 2021-22) Ta. Abdasa-Kutch  
Estimated Cost Rs. 5,39,48,261.20 (Tender I.D No. 506063)  
Tender can be downloaded after Dt:11/02/2022 Last Date of online Submission is till Dt:14/03/2022 at 18:00 Hours. Further details are available on the Website <http://www.gvssb.mprocare.com>  
Harding the problem of drinking water in rural areas. It is requested to contact the helpline no. 1916/1800 200 1400 of Gujarat Water Supply & Sewerage Board, Gandhinagar.  
DD/KUTCH/1031/2022



**adani wilmar**  
**ADANI WILMAR LIMITED**

Registered Office: "Fortune House", Nr Navrangpura Railway Crossing, Navrangpura, Ahmedabad - 380 009. CIN : U15146GJ1999PLC035320  
Phone: 079-26455650; Fax: 079-26455621; Email: investor.relations@adanwilmar.in  
Website: www.adanwilmar.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2021

Sr. No.	Particulars	Quarter ended		
		December 31, 2021	December 31, 2021	December 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue from Operations	14,378.66	39,253.18	10,229.49
2	Net Profit for the period before taxes and Share in profit/(loss) of Joint Ventures (before Exceptional and/or Extraordinary items)	306.29	760.48	171.33
3	Net Profit for the period before taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	306.29	760.48	171.33
4	Net Profit for the period after taxes and before Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	220.52	555.12	110.02
5	Net Profit for the period after taxes and after Share in profit/(loss) of Joint Ventures (after Exceptional and/or Extraordinary items)	211.41	569.45	127.39
6	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and other Comprehensive income (after tax)]	209.69	563.87	127.10
7	Paid-Up Equity Share Capital (Face Value of ₹ 1 Each)	114.29	114.29	114.29
8	Earnings Per Share (Face Value of ₹ 1 Each) Basic and Diluted (in ₹) (Not Annualised)	1.85	4.98	1.11

**Notes:**  
1. The aforesaid results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 14, 2022.  
2. The Statutory Auditors have carried out limited review of consolidated financial results of the Company for the quarter and nine months ended on December 31, 2021.  
3. Additional information on Standalone Financial Results is as follows: (₹ in Crores)

Sr. No.	Particulars	Quarter ended		
		December 31, 2021	December 31, 2021	December 31, 2020
		(Unaudited)	(Unaudited)	(Unaudited)
a	Revenue from Operations	13,763.47	38,087.75	10,229.49
b	Profit Before Tax	322.34	785.32	172.07
c	Profit After Tax	240.66	584.85	111.02

4. The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financial Results for the quarter and nine months ended on December 31, 2021 are available on the Stock Exchange websites ([www.bseindia.com](http://www.bseindia.com) / [www.nseindia.com](http://www.nseindia.com)) and Company's website [www.adanwilmar.com](http://www.adanwilmar.com).

For and on behalf of the Board of Directors  
**Angshu Mallick**  
Managing Director and Chief Executive Officer

Place: Ahmedabad  
Date: February 14, 2022

Adfactors 587

**ATUL AUTO LIMITED**

Reg. Office : Survey No. 86, Plot No. 1 to 4, 8-B, National Highway, Near Microwave Tower, Shapar (Veraval), Dist. Rajkot, Gujarat 360 024 CIN L54100GJ1986PLC016999 | Website: www.atulauto.co.in | E-Mail: info@atulauto.co.in

Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Nine Months ended on December 31, 2021

Sr. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter Ended		Nine Months Ended	Quarter Ended		Nine Months Ended
		31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)	31.12.2021 (Unaudited)	31.12.2020 (Unaudited)	31.12.2021 (Unaudited)
1	Total income from Operation (Net)	9,377	10,171	20,796	10,284	10,171	22,058
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	(1,156)	131	(2,593)
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extra ordinary Items)	(1,134)	137	(2,549)	(1,156)	131	(2,593)
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extra ordinary Items)	(852)	106	(1,920)	(881)	100	(1,975)
5	Total Comprehensive Income for the period [Comprising Profit/(loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(846)	99	(1,910)	(874)	118	(1,927)
6	Paid up Equity Share Capital	1,097	1,097	1,097	1,097	1,097	1,097
7	Earning Per Share (Basic and Diluted but not annualised) (Face value of Rs. 5/-)	(3.88)	0.47	(8.75)	(4.02)	0.57	(8.76)

**Note:**  
The above is an extract of the detailed format of Quarterly Financial Results (Standalone and Consolidated) filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results for the said Quarter and Nine Months end are available on Stock Exchanges Websites : [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com). The same is also available on the website of the Company: [www.atulauto.co.in](http://www.atulauto.co.in)

For and on behalf of Board of Directors of Atul Auto Limited  
**Jayantibhai J Chandra**  
Chairman & Managing Director  
(DIN : 00057722)

Date : February 12, 2022  
Place : Shapar (Dist. Rajkot)



ADVERTORIAL

**Living with Covid 19**




**Dr Shashank R Joshi**  
MD, DM, FRCP, FICP, FACE, FACP  
Consultant Endocrinologist,  
Mumbai  
Member, Maharashtra COVID-19 Task force  
Padma Shri Awardee

SARS-CoV-2 to make significant evolutionary leaps where it may become a manageable condition in most and protecting the most vulnerable likely to deteriorate. We need to live our lives with Covid 19 with care, caution and precautions without fear and panic.

The novel coronavirus disease of 2019 is associated with significant morbidity and mortality. Our current focus is to save every life from covid 19. Most lives are lost in elderly or unvaccinated population or those who have underlying immunocompromised states or co morbid disorders like hypertension, diabetes, heart diseases or kidney or liver issues. The impact of thrombotic complications has been increasingly recognized as an important component of this disease associated with higher risk of death. To add to the burden of thromboembolism, winters are often accompanied with an unusually high occurrence of heart

attacks or strokes. Deaths from heart disease, including sudden deaths, tend to increase rapidly at the onset of winters. The risk of having a heart attack during the winter months is twice as high as during the summers. So, people with cardiometabolic conditions must take utmost care to prevent covid 19 or treat aggressively.

The quest for effective drugs to treat COVID-19 and vaccines to prevent complications has been a priority ever since the outbreak of the disease. Up to now, COVID treatment choices have been inferred from the experience with other coronaviruses or viral infection outbreaks. The options currently being used clinically are categorically divided as antivirals, immunomodulators and other drugs. However, it has been observed that the use of such drugs has shown both, limited efficacy & specificity against SAR-COV-2 but evidence continues to be generated. Many of these medicines were repurposed and are still under investigation.



Lone Coronavirus battling against the host of antibodies.

Flu and influenzas pandemics have ravaged the world since 1918 till date. Covid 19 had also seen waves and strains evolve which has seen it evolve from a life-threatening pneumonia like disease from the Wuhan strain till the current less severe Omicron strain which is flu like syndrome in most people now. Omicron related tsunami like wave is less severe but highly contagious. The manifestations of Omicron are essentially an upper airway disease which is "nose" and "throat" covid. They are fever, nasal congestion/stuffy or blocked nose, sore throat with pain, cough, headache, bodyache, tiredness (fatigue), myalgia (muscle pain) and many others. The lung covid which was seen in the Delta strain can still rarely exist often may have loss of smell and taste should never be missed. Monitoring temperature and oxygen saturation will always be the key in the first week particularly. Symptomatic treatment is the key with antipyretics, anti-inflammatory, antihistamines and simple immunity stimulating micronutrients. So current mild disease can be managed by symptomatic treatment solutions and red flagging the vulnerable groups. Simple medicines like low dose aspirin, statins or anticoagulants save lives in the high risk cardiometabolic co morbidities like diabetes and heart diseases.

Now, there is a need to start living with Covid 19 ensuring to follow universal behaviour of masking, air-ventilation, distancing, and sanitisation, behave responsibly and stay safe.

**Need of the Hour : Boost Immunity**



**Rohit Shelatkar**  
B Pharmacy, MSc. Pharmacology,  
Sr. Vice President, Director,  
Vitabiotics Ltd. UK

Heads the international business team along with his participation in the Product Formulations and Regulatory Affairs.

For those who had hoped that 2021 would be the year that put the pandemic in the past tense, it was a harsh reminder that it is still very much present. Rather than laying plans to return to the 'normal' life we knew before the pandemic, 2022 is the year the world must come to terms with the fact that SARS-CoV-2 is here to stay.

While COVID-19 is prevalent, the combined use of immunomodulatory or

anti-inflammatory agents and antivirals might be the optimal therapy for the disease. The emergence of affordable and powerful oral anti-COVID-19 drugs and the increased uptake of vaccination will bring hope for the end of the COVID-19 pandemic.

It takes years to develop antiviral drugs & looking at repurposing easily accessible which treat COVID symptoms. The need of the hour is to look at therapies that can be taken at home in tablet form to reduce hospital load. Knowledge & detailed science behind use of aspirin & promethazine in treating flu like symptoms backed by clinical evidence is sufficiently available.

Micronutrient have potential roles in interfering with virus at the entry site, and inhibiting activities of replication cycle of severe acute respiratory syndrome coronavirus Micro-nutrient also have immunomodulating, anti-inflammatory, antioxidant, and antiviral properties. Therefore, micronutrients are consequently a promising alternative nutritional approach to combat COVID-19.

Vitamin D supplementation is safe and effective up to 4,000 IU in reducing virus replication and controlling the cytokine storm.

In COVID, vitamin C up to 1500 mg provides optimum in COVID-19. Vitamin B3 not only helps to build and maintain a healthy immune system but it could potentially prevent or reduce COVID-19 symptoms or treat SARS-CoV-2 infection. Zinc has immunomodulatory, antiviral & anti-inflammatory responses and supplementing 15-30 mg Zinc per day in COVID infected is effective. Selenium and Iodine has beneficial effects on immunity, with a dose more than 100 µg per day.

The COVID-19 pandemic is still severe, and most of the drugs currently for COVID-19 are not designed specifically against SARS-CoV-2. The combination of Aspirin, Promethazine and micronutrients inhibits viral proliferation in early stage of COVID-19 thus preventing subsequent severe complications. Clinical evidence suggests that Aspirin, promethazine and micronutrients can shorten the recovery time of COVID-19 symptoms.

Need of the hour with omicron variant is to boost immunity of those vaccinated & unvaccinated as emerging variants tend to cause mild illness. Clearly better vaccines will take years to develop and right now what we need is widely available & safe, affordable therapies.

Issued in Public Interest by Vitabiotics Ltd.

